Literature DB >> 23760288

Long-term hemodynamic and molecular effects persist after discontinued renin-angiotensin system blockade in patients with type 1 diabetes mellitus.

David Z I Cherney1, Bernard Zinman, Christopher R J Kennedy, Rahim Moineddin, Vesta Lai, Stuart Yang, Judith A Miller, Stephenie D Prokopec, Paul C Boutros, James W Scholey, Heather N Reich.   

Abstract

Animal studies suggest temporary renin-angiotensin system (RAS) blockade enhances long-term vascular protective effects; however, this is not established in humans. Here we evaluated the long-term effects of prior RAS blockade on hemodynamic function, urinary measures of inflammation, and tissue antioxidant mRNA expression in patients with type 1 diabetes mellitus (T1DM) who participated in the 5-year Renin Angiotensin System Study (RASS). At 4 years after completing the RASS and discontinuing study medication, renal hemodynamic responses to clamped hyperglycemia were significantly greater in 18 patients in the RAS blockade group compared to 9 patients of the placebo-treated group. Individuals who had received RAS blockade also exhibited higher flow-mediated vasodilatation, reduced urinary cytokine excretion in response to hyperglycemia, and increased skin mRNA expression of superoxide dismutase-1 and catalase. Thus, patients with uncomplicated T1DM who received prior RAS blockade for 5 years maintain long-term effects on renal hemodynamic and systemic vascular function, inflammatory pathways in the kidney, and antioxidant enzyme expression in skin 4 years after discontinuation of therapy. Our findings suggest that sustained long-term protective effects of finite RAS inhibition requires further study.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23760288     DOI: 10.1038/ki.2013.221

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

1.  Diabetes: Legacy effects of RAS blockade in diabetes mellitus.

Authors:  Christos Chatzikyrkou; Jan Menne
Journal:  Nat Rev Nephrol       Date:  2013-09-10       Impact factor: 28.314

2.  Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes.

Authors:  Julie A Lovshin; Yuliya Lytvyn; Leif E Lovblom; Alexandra Katz; Geneviève Boulet; Petter Bjornstad; Vesta Lai; Leslie Cham; Josephine Tse; Andrej Orszag; Hillary A Keenan; Narinder Paul; Vera Bril; David T Wong; Kylen D McReelis; Michael H Brent; Bruce A Perkins; David Z I Cherney
Journal:  Diabetes Care       Date:  2018-12-06       Impact factor: 19.112

3.  Long-term Effect of Losartan on Kidney Disease in American Indians With Type 2 Diabetes: A Follow-up Analysis of a Randomized Clinical Trial.

Authors:  Stephanie K Tanamas; Pierre-Jean Saulnier; Gudeta D Fufaa; Kevin M Wheelock; E Jennifer Weil; Robert L Hanson; William C Knowler; Peter H Bennett; Robert G Nelson
Journal:  Diabetes Care       Date:  2016-09-09       Impact factor: 19.112

4.  Downregulation of Salusin-β protects renal tubular epithelial cells against high glucose-induced inflammation, oxidative stress, apoptosis and lipid accumulation via suppressing miR-155-5p.

Authors:  Hongmei Chen; Genjuan Jin
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.

Authors:  Jan Menne; Eberhard Ritz; Luis M Ruilope; Christos Chatzikyrkou; Giancarlo Viberti; Hermann Haller
Journal:  J Am Heart Assoc       Date:  2014       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.